Status:
COMPLETED
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Stroke
Eligibility:
All Genders
18+ years
Brief Summary
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-P...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients registered in the ZSQCC platform from Jan 2017 to Mar 2020
- ≥ 18 years of age
- Diagnosed with AIS at admission
- Arrived or admitted to the hospital within 4.5 hours of symptom onset
- If treated with IV rt-PA: received IV rt-PA within 4.5 hours of symptom onset
- Exclusion criteria:
- Documented Intravenous Thrombolysis (IVT) contraindication except age to IV rt-PA treatment according to the Summary of Product Characteristics (SmPC)
- Missing any one of the key data (age, gender, baseline National Institutes of Health Stroke Scale \[NIHSS\], time of symptom onset, time of hospital arrival or admission, IVT or not, time of IV rt-PA treatment)
- Received thrombolysis agents other than rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)
- Received endovascular treatment
- Received IV rt-PA after 4.5 hours of symptom onset
Exclusion
Key Trial Info
Start Date :
April 12 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
12551 Patients enrolled
Trial Details
Trial ID
NCT05395338
Start Date
April 12 2022
End Date
November 30 2022
Last Update
October 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim (China) Investment Co., ltd.
Shanghai, China, 200040